2023-503823-24-01招募中1 期
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 65
- 试验地点
- 22
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GSM-CT
Scientific
Celgene Corp.
研究点 (22)
Loading locations...
相似试验
进行中（未招募）
1 期
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. Phase I/II clinical trial (MERMAID1)EUCTR2021-003409-23-PLMedical University of Warsaw20
进行中（未招募）
1 期
T cell therapy for patients with leukemia or lymphomaCD19+ B cell lymphoma or leukemiaEUCTR2013-001393-19-SEppsala university30
招募中
1 期
Immune cell therapy in patients with relapsed or resistant B-AIRCT20200413047063N5Omid cell and tissue processing company10
招募中
1 期
Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after Bone Marrow TransplantACTRN12617001579381Western Sydney Local Health District, Westmead Hospital20
招募中
1 期
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune DiseasesAutoimmune DiseasesNCT06688799Beijing GoBroad Hospital18